%0 Journal Article
%T 结核分枝杆菌耐药机制的研究进展<br>Research Progress on the Drug Resistance Mechanism of <i>Mycobacterium </i><i>tuberculosis</i>
%A 庞佳琦
%A 郑改焕
%J Advances in Clinical Medicine
%P 112-119
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1471989
%X 结核病(Tuberculosis, TB)是由结核分枝杆菌(<i>Mycobacterium tuberculosis</i>, MTB)引发的慢性传染病，不仅有极高的致死性，更是全球公共卫生领域所面临的巨大挑战。而耐药结核的出现更是给这一挑战雪上加霜。耐药结核是指患者体内的MTB在进化的过程中，躲避宿主的免疫监控，进而降低抗结核药物效力。这一现象的背后，与抗生素的滥用、抗结核药物的不规范使用以及MTB自身的演变等因素紧密相连。面对这一严峻的现实，对MTB的耐药机制进行深入的研究不仅有助于我们更好地理解这一疾病的本质，更能为后续的快速分子诊断工具的开发以及新型抗结核药物的研发提供参考。<br />
Tuberculosis (TB) is a chronic infectious disease caused by <i>Mycobacterium tuberculosis</i> (MTB). It is not only extremely lethal, but also a huge challenge facing the global public health field. The emergence of drug-resistant tuberculosis has made this challenge even worse. Drug-resistant tuberculosis (TB) refers to the continuous evolution of MTB in the patient’s body, which makes it evade the immune surveillance of the host, reduces the efficacy of anti-tuberculosis drugs. Antibiotic abuse, non-standard use of anti-tuberculosis drugs, and the evolution of MTB itself are all causes of MTB resistance. Faced with this grim reality, in depth research on the drug resistance mechanism of MTB will not only help us better understand the nature of this disease, but also provide a reference for the subsequent development of rapid molecular diagnostic tools and the research and development of new anti-tuberculosis drugs.
%K 固有性耐药，获得性耐药，耐药结核，抗结核药物<br>Primary Drug Resistance
%K Acquired Drug Resist
%K Drug-Resistant Tuberculosis
%K Antituberculosis Drugs
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=91075